Why patent battles over CRISPR could slow down affordable gene therapies
I’ve been following CRISPR’s arc from laboratory curiosity to headline-making promise for years, and one thing keeps nagging at me: the technology’s potential to deliver affordable, widely available gene therapies is being tangled up by patent fights. Those legal battles aren’t just academic squabbles over who gets credit — they have real consequences for the pace of innovation, who can develop treatments, and ultimately how much...